NCCN Guidelines Insights: Hodgkin Lymphoma, Version 2.2022. Journal of the National Comprehensive Cancer Network : JNCCN Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Armand, P., Bello, C. M., Benitez, C. M., Chen, W., Dabaja, B., Daly, M. E., Gordon, L. I., Hansen, N., Herrera, A. F., Hochberg, E. P., Johnston, P. B., Kaminski, M. S., Kelsey, C. R., Kenkre, V. P., Khan, N., Lynch, R. C., Maddocks, K., McConathy, J., Metzger, M., Morgan, D., Mulroney, C., Pullarkat, S. T., Rabinovitch, R., Rosenspire, K. C., Seropian, S., Tao, R., Torka, P., Winter, J. N., Yahalom, J., Yang, J. C., Burns, J. L., Campbell, M., Sundar, H. 2022; 20 (4): 322-334


Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.

View details for DOI 10.6004/jnccn.2022.0021

View details for PubMedID 35390768